Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
12 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Vertiv fell for an 11th consecutive session, its longest losing streak since listing in 2020, and is down nearly 20% since Oct. 6. Analysts have cut several price targets but mostly maintained bullish ratings; the article cites an average target of $314.
Ratings actions from Benzinga
President Donald Trump and First Lady Melania Trump welcomed Chinese President Xi Jinping and his wife on a red carpet at Joint Base Andrews on Wednesday, kicking off a three-day visit amid tensions over trade, artificial intelligence, and Taiwan. Chinese President said that the U.S. and China, as leading artificial-in
JPMorgan raised its price target on Vertex Pharmaceuticals to $560 from $515, according to Benzinga via TradingView.
U.S. equities fell at midday Wednesday as Brent crude topped $100 a barrel and the 10-year Treasury yield climbed to a three-year high, reviving inflation and rate-hike concerns. Energy was the only S&P 500 sector in positive territory.
VRT said it has raised revenue growth targets on strong global demand and an expanding solutions portfolio, supported by power and cooling innovation, acquisitions, and operational improvements. The company is allocating capital to R&D and capacity.
VRT raised its revenue growth targets citing strong global demand and an expanding solutions portfolio, including power and cooling innovations from acquisitions. The company also pointed to operational efficiency and a balanced capital strategy supporting margin expansion.
Morgan Stanley announced a $665.00 per-share price target for Vertex Pharmaceuticals.
Analysts lifted price targets on Main Street Capital, Washington Trust Bancorp and Virtus Investment Partners while keeping or changing ratings, with the note also citing each stock’s dividend yield and recent news items.
RBC Capital raised the firm's price target on Vertex Pharmaceuticals to $570 from $543 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in June relative to th
Vertiv's target price increases due to growing AI infrastructure demand. The company's stock may see upward movement.
TD Cowen increases price target on Vertiv. Upgrade may boost stock.